Year-end Sale % OFF 
Abstract
Hematological and biochemical parameters were evaluated in 31 patients receiving 150 MBq 89Strontium (89Sr) intravenously due to painful skeletal metastases from hormone resistant prostate cancer. Two and 3 months after the injection prostate specific antigen (PSA) had increased by a median of 36% and 100%, respectively, as compared to the pretreatment value whereas alkaline phosphatase (APHOS) had decreased by about 20% (median). The leucocyte and platelet counts were reduced by about 20-35%, without reaching grade greater than or equal to 2 toxicity. Pain relief was reported in 14 of 29 evaluable patients at 2 months and in 11 of 23 patients at 3 months. It is concluded that 89Sr represents a worthwhile therapeutic modality in the palliation treatment of patients with hormone resistant prostate cancer, though the biological significance of frequently increasing PSA and decreasing APHOS is not yet completely understood.
Highlights
MethodsFrom December 1990 to February 1992 31 patients with hormone resistant prostatic cancer and painful metastases (Table I) were included in a phase II study which evaluated the palliation effect of 89Sr (Amersham, International plc, Amersham, Bucks, England)
Pain relief was reported in 14 of 29 evaluable patients at 2 months and in 11 of 23 patients at 3 months
One principal aim of the treatment of hormone resistant prostate cancer is the relief of mestastatic bone pain (Tannock et al, 1989; Zelefsky et al, 1989)
Summary
From December 1990 to February 1992 31 patients with hormone resistant prostatic cancer and painful metastases (Table I) were included in a phase II study which evaluated the palliation effect of 89Sr (Amersham, International plc, Amersham, Bucks, England). All patients underwent 99mTc bone scan which was quantitated according to Soloway et al (1988) (0: No hot spots; 1: 1-5 hot spots; 2: 6-20 hot spots; 3: > 20 hot spots; 4: Superscan = > 75% involvement of vertebrae, ribs, pelvis). Eligibility criteria were: Performance status < 2 The patients received 150 MBq 89Sr intravenously at the outpatient clinic. All patients were informed about hygienic precautions at home during the first week after the injection in order to avoid uncontrolled spread of the radioactive substance by urine or blood. Received 18 November 1991; and in revised 2 March 1992
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
